Levosimendan Intermedia CAS 36725-28-7 Puritas >99.5% (HPLC) Factory
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone (CAS: 36725-28-7) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Nomen chemicum | 6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone |
Synonyma | 6-(p-Aminophenyl) -5-methyl-4,5-dihydro-3(2H)-pyridazinone;1,4-Dihydro-4-Methyl-3-(4-Aminophenyl)pyridazine-6(5H)-one;Levosimendan Impuritas 5 |
CAS Number | 36725-28-7 |
CATTUS Number | RF-PI1976 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C11H13N3O |
M. Pondus | 203.25 |
Liquescens punctum | 194.0 ad 198.0℃ |
Density | 1.30±0.10 g/cm3 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Off-White ut pallide Brownish Color pulveris |
Lepidium sativum (HPLC) | HPLC RT maioris cacuminis respondet illi qui in-domo laborantis vexillum |
Damnum in Siccatio | <0.50% |
Residere in Ignition | <0.20% |
Substantiae cognatae | (HPLC) |
una immunditia | <0.20% |
Totalis immunditias | <0.50% |
Puritas / Analysis Methodus | >99.5% (HPLC) |
Metalla gravis | <20ppm |
Proton NMR Spectrum | Conformat ut Structure |
Test Standard | Enterprise Standard |
Consuetudinem | Medium Levosimendanum (CAS: 141505-33-1) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone (CAS: 36725-28-7) medium est Levosimendan (CAS: 141505-33-1).Levosimendan in Suetia introducta est sicut iv infusio ad defectum cordis acutorum tractandum vel refractionis symptomata defectum cordis chronici in casibus in quibus curatio conventionalis (exempli gratia diuretica vel ACE inhibitor) non sufficit.Etiam ventricularem et arterialem adenostne triphosphato-regulatos canales potassii movet, qui vasodilatationem in musculo vasculari lenis et myocardium contra infarctionem tuetur.Humilis eius phosphodiesterasis III inhibenda actio verisimiliter non est responsabilis pro effectibus positivis inotropicis, lusitropicis et dilatatis.Dissimilis alia medicamenta cardiotonica, levosimendan positivos effectus inotropicos producere potest sine relaxatione myocardiali prolongata vel incidentia arrythmiarum malignarum augendarum.Monstratum est amet periculum mortalitatis inferiorem habere defectum cordis patientibus cum placebo et dobutamine comparatum.Cum maiorem potentiam habeat, levosimendan nunc sub ulteriore aestimatione clinica sicut curatio chronica pro defectu cordis congestivi.